We are live on ! Find out more
FRTX

Fresh Tracks Therapeutics, Inc. Common Stock

Delisted

FRTX was delisted on the 18th of December, 2023.

27 hedge funds and large institutions have $6.08M invested in Fresh Tracks Therapeutics, Inc. Common Stock in 2021 Q1 according to their latest regulatory filings, with 9 funds opening new positions, 13 increasing their positions, 0 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

50% more first-time investments, than exits

New positions opened: 9 | Existing positions closed: 6

38% more capital invested

Capital invested by funds: $4.4M → $6.08M (+$1.68M)

8% more funds holding

Funds holding: 2527 (+2)

Holders
27
Holders Change
+2
Holders Change %
+8%
% of All Funds
0.47%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
9
Increased
13
Reduced
Closed
6
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
AFM
26
Anson Funds Management
Texas
-$1.04M -29,648 Closed
Millennium Management
27
Millennium Management
New York
-$255K -7,261 Closed
MFG
28
Magnus Financial Group
New York
-$82K -2,334 Closed
Squarepoint
29
Squarepoint
New York
-$65K -1,862 Closed
TRCT
30
Tower Research Capital (TRC)
New York
-$6K -175 Closed
UBS Group
31
UBS Group
Switzerland
-$4.06K -74 Closed
Bank of America
32
Bank of America
North Carolina
+$275 +5 +71%

FRTX Hedge Fund Activity: Q1 2021 in Review

27 of the 5,696 institutional investors tracked by Wall St. Rank reported a position in Fresh Tracks Therapeutics, Inc. Common Stock (FRTX) for Q1 2021, worth a combined $6.08M — up 38% from $4.4M a quarter earlier.

Buyers outnumbered sellers: 9 funds opened new FRTX positions and 6 closed out — a net gain of 3 holders — while 13 added to existing stakes and 0 trimmed.

The largest buyer was Vanguard Group, adding an estimated $547K. The largest seller was Anson Funds Management, exiting entirely with an estimated $1.04M sold.

  • 27 institutional investors held Fresh Tracks Therapeutics, Inc. Common Stock (FRTX) as of Q1 2021, up from 25 in Q4 2020.
  • Funds reported $6.08M of Fresh Tracks Therapeutics, Inc. Common Stock stock for Q1 2021, up 38% quarter-over-quarter.
  • 9 funds opened new Fresh Tracks Therapeutics, Inc. Common Stock positions in Q1 2021 and 6 closed out, a net change of +3 holders.
  • The largest Fresh Tracks Therapeutics, Inc. Common Stock buyer in Q1 2021 was Vanguard Group, an estimated $547K added.
  • The largest Fresh Tracks Therapeutics, Inc. Common Stock seller in Q1 2021 was Anson Funds Management, an estimated $1.04M sold.

Based on aggregated 13F filings for Q1 2021.